Compare PepsiCo, Inc. (PEP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Sanofi SA — how do they compare? PepsiCo, Inc. trades at $125.97 (market cap $174.89B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Sanofi SA for 94 Days on average.
| PEP | SNY | |
|---|---|---|
Market Cap | $174.89B | $95.18B |
Volume | 23,968,864 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $52.34 |
52-Week Low | $123.64 | $39.51 |
Typical Hold Time | 107 Days | 94 Days |
Enterprise Value | $215.61B | $114.48B |
Dividend Yield | 4.61% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $128.88, up 4.24% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 10.78% net income margin and 51.59% ROE. Recent news highlights price adjustments for snack products and sponsorship changes, while analysts maintain a consensus price target of $146.77 representing 13.9% upside potential from current levels.
PepsiCo presents a mixed investment case with strong profitability metrics and consistent earnings beats offset by bearish technical indicators and margin pressure from recent price cuts. The company's stable cash flow generation and dividend payments provide downside protection, though competitive pressures and consumer resistance to higher prices remain key risks. Wall Street sentiment leans cautious with 67.4% hold ratings.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
